Trial Outcomes & Findings for A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients (NCT NCT01947894)

NCT ID: NCT01947894

Last Updated: 2019-11-20

Results Overview

IGF-I along with growth hormone helps promote normal bone and tissue growth and development. Categories for assessment for participant's post-baseline IGF-I values: (1) IGF-I LLN = if any of assessments of IGF-I post-baseline visit was lower than lower limit of normal (LLN); (2) IGF-I ULN = If any of assessments of IGF-I post-baseline visit was greater than upper level of normal (ULN); (3) IGF-I unknown = no IGF-I reported; (4) Within reference range = IGF-I levels within normal range. Following is normal reference range of IGF-I in nanogram per milliliter. 18 Years of age (Y): Male =162-541, Female =170-640; 19 Y: Male =138-442, Female =147-527; 20 Y: Male =122-384,Female =132-457; 21-25 Y=116-341; 26-30 Y=117-321; 31-35 Y=113-297; 36-40 Y=106-277; 41-45 Y =98-261; 46-50 Y=91-246; 51-55 Y=84-233; 56-60 Y=78-220; 61-65 Y=72-207; 66-70 Y=67-195; 71-75 Y=62-184; 76-80 Y=57-172; \>80 Y=53-162. There was no differentiation for male and female in normal range of IGF-I after 20 years of age.

• Recruitment status: COMPLETED
• Target enrollment: 377 participants
• Primary outcome timeframe: Up to 5 years (after baseline visit)
• Results posted on: 2019-11-20

Participant Flow

Participant milestones

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Overall Study STARTED	247	42	88
Overall Study Treated	246	41	87
Overall Study COMPLETED	160	24	61
Overall Study NOT COMPLETED	87	18	27

Reasons for withdrawal

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Overall Study Other	3	4	3
Overall Study Withdrawal by Subject	12	4	1
Overall Study Death	12	1	0
Overall Study Physician Decision	2	0	0
Overall Study Adverse Event	5	1	0
Overall Study Switched to other growth hormone brand	53	8	23

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=247 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=42 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=88 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Total n=377 Participants Total of all reporting groups
Age, Customized 0 to less than or equal to (<=) 18 Years	0 Participants n=247 Participants	0 Participants n=42 Participants	0 Participants n=88 Participants	0 Participants n=377 Participants
Age, Customized Greater than (>) 18 to less than (<) 65 Years	138 Participants n=247 Participants	38 Participants n=42 Participants	83 Participants n=88 Participants	259 Participants n=377 Participants
Age, Customized >=65 Years	100 Participants n=247 Participants	4 Participants n=42 Participants	2 Participants n=88 Participants	106 Participants n=377 Participants
Age, Customized Unknown	9 Participants n=247 Participants	0 Participants n=42 Participants	3 Participants n=88 Participants	12 Participants n=377 Participants
Sex: Female, Male Female	120 Participants n=247 Participants	22 Participants n=42 Participants	42 Participants n=88 Participants	184 Participants n=377 Participants
Sex: Female, Male Male	127 Participants n=247 Participants	20 Participants n=42 Participants	46 Participants n=88 Participants	193 Participants n=377 Participants
Race and Ethnicity Not Collected	—	—	—	0 Participants Race and Ethnicity were not collected from any participant.

PRIMARY outcome

Timeframe: Up to 5 years (after baseline visit)

Population: Full analysis set (FAS) included all correctly enrolled participants who received at least 1 dose of Genotropin. Erroneously enrolled participants were excluded from FAS, as they did not meet the inclusion criteria or met an exclusion criterion, which was discovered after enrolment to the study.

IGF-I along with growth hormone helps promote normal bone and tissue growth and development. Categories for assessment for participant's post-baseline IGF-I values: (1) IGF-I LLN = if any of assessments of IGF-I post-baseline visit was lower than lower limit of normal (LLN); (2) IGF-I ULN = If any of assessments of IGF-I post-baseline visit was greater than upper level of normal (ULN); (3) IGF-I unknown = no IGF-I reported; (4) Within reference range = IGF-I levels within normal range. Following is normal reference range of IGF-I in nanogram per milliliter. 18 Years of age (Y): Male =162-541, Female =170-640; 19 Y: Male =138-442, Female =147-527; 20 Y: Male =122-384,Female =132-457; 21-25 Y=116-341; 26-30 Y=117-321; 31-35 Y=113-297; 36-40 Y=106-277; 41-45 Y =98-261; 46-50 Y=91-246; 51-55 Y=84-233; 56-60 Y=78-220; 61-65 Y=72-207; 66-70 Y=67-195; 71-75 Y=62-184; 76-80 Y=57-172; >80 Y=53-162. There was no differentiation for male and female in normal range of IGF-I after 20 years of age.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Number of Participants Classified According to Insulin-like Growth Factor (IGF-I) Assessments IGF-I LLN	11 Participants	2 Participants	4 Participants
Number of Participants Classified According to Insulin-like Growth Factor (IGF-I) Assessments IGF-I ULN	63 Participants	8 Participants	30 Participants
Number of Participants Classified According to Insulin-like Growth Factor (IGF-I) Assessments IGF-I ULN within reference range	159 Participants	22 Participants	47 Participants
Number of Participants Classified According to Insulin-like Growth Factor (IGF-I) Assessments IGF-I Unknown	13 Participants	6 Participants	6 Participants

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: Safety analysis set included all enrolled participants who received at least 1 dose of Genotropin.

An AE was any untoward medical occurrence in a participant who received Genotropin without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=41 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) AEs	103 Participants	17 Participants	22 Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) SAEs	57 Participants	5 Participants	10 Participants

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: Safety analysis set included all enrolled participants who received at least 1 dose of Genotropin. "Overall Number of Participants Analyzed" = number of participants evaluable for this outcome measure.

Treatment-related AEs refer to AEs that have a causal relationship with the treatment or usage. If there was any relationship between AE and Genotropin treatment,that was judged by investigator.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=103 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=17 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=22 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Number of Treatment Related Adverse Events	8 adverse events	2 adverse events	0 adverse events

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: Safety analysis set included all enrolled participants who received at least 1 dose of Genotropin. "Overall Number of Participants Analyzed" = number of participants evaluable for this outcome measure.

An AE is any untoward medical occurrence in a participant administered a medicinal product that need not necessarily have a causal relationship with the product treatment or usage. An SAE is any untoward medical occurrence in a participant administered a medicinal or nutritional product at any dose that resulted to death, life-threatening, hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); and congenital anomaly/birth defect.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=103 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=117 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=22 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Number of Adverse Events Leading to Withdrawal of Genotropin Treatment	14 adverse events	2 adverse events	1 adverse events

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: Safety analysis set included all enrolled participants who received at least 1 dose of Genotropin.

An AE is any untoward medical occurrence in a participant administered a medicinal product that need not necessarily have a causal relationship with the product treatment or usage. An SAE is any untoward medical occurrence in a participant administered a medicinal or nutritional product at any dose that resulted to death, life-threatening, hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); and congenital anomaly/birth defect. Participants who discontinued study due to AEs were reported.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=41 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Number of Participants Who Discontinued Study Due to Adverse Events	5 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Weight of participants was measured in kilograms (kg).

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Weight of Participants at Baseline, Years 1, 2, 3, 4 and 5 Baseline	83.8 kg Standard Deviation 16.76	82.4 kg Standard Deviation 19.68	86.9 kg Standard Deviation 26.11
Weight of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 1	83.9 kg Standard Deviation 18.09	86.4 kg Standard Deviation 15.54	84.3 kg Standard Deviation 25.11
Weight of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 2	82.8 kg Standard Deviation 15.66	86.8 kg Standard Deviation 15.54	87.7 kg Standard Deviation 20.73
Weight of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 3	85.4 kg Standard Deviation 18.91	84.3 kg Standard Deviation 17.67	89.4 kg Standard Deviation 24.08
Weight of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 4	82.4 kg Standard Deviation 17.83	97.2 kg Standard Deviation 9.20	82.5 kg Standard Deviation 20.66
Weight of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 5	79.5 kg Standard Deviation 16.00	—	104.4 kg Standard Deviation 0.85

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Weight of participants was measured in kg.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Change From Baseline in Weight of Participants at Years 1, 2, 3, 4 and 5 Change at Year 1	0 kg Standard Deviation 6.55	-2.0 kg Standard Deviation 15.37	-2.3 kg Standard Deviation 21.49
Change From Baseline in Weight of Participants at Years 1, 2, 3, 4 and 5 Change at Year 2	-0.7 kg Standard Deviation 6.82	-1.6 kg Standard Deviation 12.85	1.0 kg Standard Deviation 5.65
Change From Baseline in Weight of Participants at Years 1, 2, 3, 4 and 5 Change at Year 3	2.2 kg Standard Deviation 11.41	-0.3 kg Standard Deviation 13.41	-2.8 kg Standard Deviation 18.16
Change From Baseline in Weight of Participants at Years 1, 2, 3, 4 and 5 Change at Year 4	-1.6 kg Standard Deviation 8.44	6.6 kg Standard Deviation 7.24	-0.3 kg Standard Deviation 7.52
Change From Baseline in Weight of Participants at Years 1, 2, 3, 4 and 5 Change at Year 5	-2.2 kg Standard Deviation 8.02	—	-12.9 kg Standard Deviation 20.22

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Height of participants was measured in centimeters.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Height of Participants at Baseline, Years 1, 2, 3, 4 and 5 Baseline	171.7 centimeters (cm) Standard Deviation 9.39	172.2 centimeters (cm) Standard Deviation 10.67	171.7 centimeters (cm) Standard Deviation 11.81
Height of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 1	171.9 centimeters (cm) Standard Deviation 9.50	174.0 centimeters (cm) Standard Deviation 10.01	170.6 centimeters (cm) Standard Deviation 11.88
Height of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 2	172.0 centimeters (cm) Standard Deviation 9.20	172.7 centimeters (cm) Standard Deviation 9.90	171.4 centimeters (cm) Standard Deviation 12.13
Height of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 3	172.1 centimeters (cm) Standard Deviation 9.68	172.5 centimeters (cm) Standard Deviation 10.45	172.8 centimeters (cm) Standard Deviation 11.54
Height of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 4	173.0 centimeters (cm) Standard Deviation 9.40	172.5 centimeters (cm) Standard Deviation 7.95	172.0 centimeters (cm) Standard Deviation 11.60
Height of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 5	171.0 centimeters (cm) Standard Deviation 11.44	—	169.1 centimeters (cm) Standard Deviation 5.80

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Height of participants was measured in centimeters.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Change From Baseline in Height of Participants at Years 1, 2, 3, 4 and 5 Change at Year 1	0 centimeters (cm) Standard Deviation 0.31	-0.1 centimeters (cm) Standard Deviation 0.78	0 centimeters (cm) Standard Deviation 0.31
Change From Baseline in Height of Participants at Years 1, 2, 3, 4 and 5 Change at Year 2	0 centimeters (cm) Standard Deviation 0.30	-0.1 centimeters (cm) Standard Deviation 0.79	0 centimeters (cm) Standard Deviation 0.17
Change From Baseline in Height of Participants at Years 1, 2, 3, 4 and 5 Change at Year 3	0 centimeters (cm) Standard Deviation 0.60	0 centimeters (cm) Standard Deviation 0	0 centimeters (cm) Standard Deviation 0.35
Change From Baseline in Height of Participants at Years 1, 2, 3, 4 and 5 Change at Year 4	0 centimeters (cm) Standard Deviation 0.56	0 centimeters (cm) Standard Deviation 0	0 centimeters (cm) Standard Deviation 0.21
Change From Baseline in Height of Participants at Years 1, 2, 3, 4 and 5 Change at Year 5	-0.1 centimeters (cm) Standard Deviation 0.52	—	0 centimeters (cm) Standard Deviation 0

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

BMI was defined as an index for assessing overweight and underweight and was obtained by dividing body weight in kilograms (kg) by height in meters squared (m^2).

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Body Mass Index (BMI) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Baseline	28.3 Kilogram per meter squared (kg/m^2) Standard Deviation 4.76	27.8 Kilogram per meter squared (kg/m^2) Standard Deviation 5.71	29.6 Kilogram per meter squared (kg/m^2) Standard Deviation 8.42
Body Mass Index (BMI) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 1	28.2 Kilogram per meter squared (kg/m^2) Standard Deviation 5.45	28.3 Kilogram per meter squared (kg/m^2) Standard Deviation 5.56	28.9 Kilogram per meter squared (kg/m^2) Standard Deviation 7.26
Body Mass Index (BMI) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 2	27.9 Kilogram per meter squared (kg/m^2) Standard Deviation 4.20	28.9 Kilogram per meter squared (kg/m^2) Standard Deviation 4.70	29.8 Kilogram per meter squared (kg/m^2) Standard Deviation 6.08
Body Mass Index (BMI) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 3	28.8 Kilogram per meter squared (kg/m^2) Standard Deviation 5.55	28.5 Kilogram per meter squared (kg/m^2) Standard Deviation 4.70	29.8 Kilogram per meter squared (kg/m^2) Standard Deviation 6.47
Body Mass Index (BMI) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 4	27.4 Kilogram per meter squared (kg/m^2) Standard Deviation 4.09	33.2 Kilogram per meter squared (kg/m^2) Standard Deviation 2.92	28.2 Kilogram per meter squared (kg/m^2) Standard Deviation 7.24
Body Mass Index (BMI) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 5	27.8 Kilogram per meter squared (kg/m^2) Standard Deviation 6.14	—	36.6 Kilogram per meter squared (kg/m^2) Standard Deviation 2.81

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

BMI was defined as an index for assessing overweight and underweight and was obtained by dividing body weight in kilograms (kg) by height in m^2.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Change From Baseline in Body Mass Index of Participants at Years 1, 2, 3, 4 and 5 Change at Year 1	0 kg/m^2 Standard Deviation 2.67	-0.4 kg/m^2 Standard Deviation 4.60	-0.9 kg/m^2 Standard Deviation 7.79
Change From Baseline in Body Mass Index of Participants at Years 1, 2, 3, 4 and 5 Change at Year 2	-0.2 kg/m^2 Standard Deviation 2.25	-0.5 kg/m^2 Standard Deviation 3.84	0.3 kg/m^2 Standard Deviation 2.03
Change From Baseline in Body Mass Index of Participants at Years 1, 2, 3, 4 and 5 Change at Year 3	0.7 kg/m^2 Standard Deviation 3.75	-0.3 kg/m^2 Standard Deviation 4.13	-1.1 kg/m^2 Standard Deviation 6.02
Change From Baseline in Body Mass Index of Participants at Years 1, 2, 3, 4 and 5 Change at Year 4	-0.4 kg/m^2 Standard Deviation 2.62	1.8 kg/m^2 Standard Deviation 2.43	-0.1 kg/m^2 Standard Deviation 2.54
Change From Baseline in Body Mass Index of Participants at Years 1, 2, 3, 4 and 5 Change at Year 5	-0.7 kg/m^2 Standard Deviation 2.85	—	-4.3 kg/m^2 Standard Deviation 6.78

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Measurement of BP included supine systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine SBP- Baseline	132.3 millimeter of mercury (mmHg) Standard Deviation 16.47	123.6 millimeter of mercury (mmHg) Standard Deviation 13.47	120.3 millimeter of mercury (mmHg) Standard Deviation 13.40
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine SBP- Year 1	132.7 millimeter of mercury (mmHg) Standard Deviation 17.82	127.4 millimeter of mercury (mmHg) Standard Deviation 16.00	122.9 millimeter of mercury (mmHg) Standard Deviation 11.74
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine SBP- Year 2	133.3 millimeter of mercury (mmHg) Standard Deviation 16.82	133.5 millimeter of mercury (mmHg) Standard Deviation 21.97	124.1 millimeter of mercury (mmHg) Standard Deviation 14.37
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine SBP- Year 3	133.4 millimeter of mercury (mmHg) Standard Deviation 15.68	130.4 millimeter of mercury (mmHg) Standard Deviation 20.13	123.4 millimeter of mercury (mmHg) Standard Deviation 14.26
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine SBP- Year 4	132.3 millimeter of mercury (mmHg) Standard Deviation 14.80	134.4 millimeter of mercury (mmHg) Standard Deviation 14.01	127.8 millimeter of mercury (mmHg) Standard Deviation 13.97
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine SBP- Year 5	137.4 millimeter of mercury (mmHg) Standard Deviation 17.76	—	121.0 millimeter of mercury (mmHg) Standard Deviation 1.41
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine DBP- Baseline	78.4 millimeter of mercury (mmHg) Standard Deviation 9.32	75.5 millimeter of mercury (mmHg) Standard Deviation 10.76	74.0 millimeter of mercury (mmHg) Standard Deviation 8.29
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine DBP- Year 1	77.1 millimeter of mercury (mmHg) Standard Deviation 9.37	73.0 millimeter of mercury (mmHg) Standard Deviation 11.00	74.6 millimeter of mercury (mmHg) Standard Deviation 9.01
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine DBP- Year 2	78.2 millimeter of mercury (mmHg) Standard Deviation 9.10	75.8 millimeter of mercury (mmHg) Standard Deviation 12.32	76.3 millimeter of mercury (mmHg) Standard Deviation 9.06
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine DBP- Year 3	79.0 millimeter of mercury (mmHg) Standard Deviation 9.04	77.2 millimeter of mercury (mmHg) Standard Deviation 10.99	76.0 millimeter of mercury (mmHg) Standard Deviation 7.84
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine DBP- Year 4	77.5 millimeter of mercury (mmHg) Standard Deviation 9.01	80.6 millimeter of mercury (mmHg) Standard Deviation 11.91	76.1 millimeter of mercury (mmHg) Standard Deviation 8.04
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5 Supine DBP- Year 5	80.6 millimeter of mercury (mmHg) Standard Deviation 12.82	—	70.5 millimeter of mercury (mmHg) Standard Deviation 0.71

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Measurement of BP included supine SBP and DBP.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine SBP- Year 1	1.0 mmHg Standard Deviation 15.67	-0.9 mmHg Standard Deviation 11.52	3.4 mmHg Standard Deviation 13.52
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine SBP- Year 2	0.4 mmHg Standard Deviation 15.78	6.1 mmHg Standard Deviation 17.48	2.3 mmHg Standard Deviation 12.81
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine SBP- Year 3	1.0 mmHg Standard Deviation 13.84	1.5 mmHg Standard Deviation 17.11	4.3 mmHg Standard Deviation 12.41
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine SBP- Year 4	-1.5 mmHg Standard Deviation 19.91	10.5 mmHg Standard Deviation 10.65	4.3 mmHg Standard Deviation 16.40
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine SBP- Year 5	5.7 mmHg Standard Deviation 19.26	—	-4.0 mmHg Standard Deviation 8.49
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine DBP- Year 1	-1.2 mmHg Standard Deviation 10.66	-4.2 mmHg Standard Deviation 10.2	0.6 mmHg Standard Deviation 9.83
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine DBP- Year 2	-0.6 mmHg Standard Deviation 10.84	0.5 mmHg Standard Deviation 11.81	1.8 mmHg Standard Deviation 8.17
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine DBP- Year 3	0.7 mmHg Standard Deviation 10.44	-0.4 mmHg Standard Deviation 8.2	0.8 mmHg Standard Deviation 8.81
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine DBP- Year 4	-1.5 mmHg Standard Deviation 12.07	-2.8 mmHg Standard Deviation 9.77	2.0 mmHg Standard Deviation 9.50
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5 Change in Supine DBP- Year 5	3.0 mmHg Standard Deviation 12.36	—	0.5 mmHg Standard Deviation 0.71

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Heart rate was measured in supine position.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Heart Rate of Participants at Baseline, Years 1, 2, 3, 4 and 5 Baseline	69.3 beats per minute (bpm) Standard Deviation 9.42	68.7 beats per minute (bpm) Standard Deviation 10.66	69.7 beats per minute (bpm) Standard Deviation 8.28
Heart Rate of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 1	70.2 beats per minute (bpm) Standard Deviation 11.22	70.7 beats per minute (bpm) Standard Deviation 13.39	74.1 beats per minute (bpm) Standard Deviation 10.79
Heart Rate of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 2	69.8 beats per minute (bpm) Standard Deviation 10.41	70.5 beats per minute (bpm) Standard Deviation 14.46	71.3 beats per minute (bpm) Standard Deviation 11.05
Heart Rate of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 3	71.5 beats per minute (bpm) Standard Deviation 9.90	69.8 beats per minute (bpm) Standard Deviation 10.59	69.0 beats per minute (bpm) Standard Deviation 11.08
Heart Rate of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 4	68.3 beats per minute (bpm) Standard Deviation 9.15	64.3 beats per minute (bpm) Standard Deviation 15.34	69.4 beats per minute (bpm) Standard Deviation 11.68
Heart Rate of Participants at Baseline, Years 1, 2, 3, 4 and 5 Year 5	68.5 beats per minute (bpm) Standard Deviation 10.92	—	70.0 beats per minute (bpm) Standard Deviation NA Standard deviation was not estimable because only 1 participant was analyzed.

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Heart rate was measured in supine position.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Change From Baseline in Heart Rate of Participants at Years 1, 2, 3, 4 and 5 Change at Year 1	1.4 bpm Standard Deviation 11.62	-1.4 bpm Standard Deviation 12.66	4.7 bpm Standard Deviation 12.06
Change From Baseline in Heart Rate of Participants at Years 1, 2, 3, 4 and 5 Change at Year 2	0.7 bpm Standard Deviation 10.57	1.8 bpm Standard Deviation 14.88	3.4 bpm Standard Deviation 11.47
Change From Baseline in Heart Rate of Participants at Years 1, 2, 3, 4 and 5 Change at Year 3	0.1 bpm Standard Deviation 13.24	1.5 bpm Standard Deviation 13.94	1.6 bpm Standard Deviation 15.11
Change From Baseline in Heart Rate of Participants at Years 1, 2, 3, 4 and 5 Change at Year 4	1.3 bpm Standard Deviation 8.97	1.0 bpm Standard Deviation 16.31	0.7 bpm Standard Deviation 9.76
Change From Baseline in Heart Rate of Participants at Years 1, 2, 3, 4 and 5 Change at Year 5	3.7 bpm Standard Deviation 13.49	—	0 bpm Standard Deviation NA Standard deviation was not estimable because only 1 participant was analyzed.

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Body composition included parameters fat mass and muscle mass.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Percentage of Participants With Body Composition Assessments at Baseline, Years 1, 2, 3 and 4 Baseline	48.78 percentage of participants	47.37 percentage of participants	58.62 percentage of participants
Percentage of Participants With Body Composition Assessments at Baseline, Years 1, 2, 3 and 4 Year 1	31.30 percentage of participants	5.26 percentage of participants	31.03 percentage of participants
Percentage of Participants With Body Composition Assessments at Baseline, Years 1, 2, 3 and 4 Year 2	33.33 percentage of participants	21.05 percentage of participants	34.48 percentage of participants
Percentage of Participants With Body Composition Assessments at Baseline, Years 1, 2, 3 and 4 Year 3	15.85 percentage of participants	21.05 percentage of participants	20.69 percentage of participants
Percentage of Participants With Body Composition Assessments at Baseline, Years 1, 2, 3 and 4 Year 4	2.03 percentage of participants	—	5.75 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4, 5

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue and blood vessels. MRI investigation uses strong magnetic field and radio waves to create detailed images of the organs and tissues within the body.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Percentage of Participants With Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Investigation at Baseline, Years 1, 2, 3, 4 and 5 Baseline	32.93 percentage of participants	42.11 percentage of participants	18.39 percentage of participants
Percentage of Participants With Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Investigation at Baseline, Years 1, 2, 3, 4 and 5 Year 1	14.63 percentage of participants	23.68 percentage of participants	6.9 percentage of participants
Percentage of Participants With Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Investigation at Baseline, Years 1, 2, 3, 4 and 5 Year 2	15.04 percentage of participants	13.16 percentage of participants	3.45 percentage of participants
Percentage of Participants With Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Investigation at Baseline, Years 1, 2, 3, 4 and 5 Year 3	11.38 percentage of participants	7.89 percentage of participants	5.75 percentage of participants
Percentage of Participants With Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Investigation at Baseline, Years 1, 2, 3, 4 and 5 Year 4	4.88 percentage of participants	5.26 percentage of participants	4.6 percentage of participants
Percentage of Participants With Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Investigation at Baseline, Years 1, 2, 3, 4 and 5 Year 5	1.63 percentage of participants	—	1.15 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Year 1, 2, 3, 4

Population: FAS was analyzed. Here, "Number analyzed" = participants who were evaluable at specified time points for each arm, respectively.

Hormones that were evaluated were thyroid stimulating hormone, adrenocorticotropic hormone, luteinizing hormone, follicle-stimulating hormone, antidiuretic hormone and prolactin hormone. Abnormalities were judged by the investigator.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=38 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Percentage of Participants With Any Change From Baseline in Hormone Abnormalities at Years 1, 2, 3, and 4 Year 1	2.03 percentage of participants	2.63 percentage of participants	1.15 percentage of participants
Percentage of Participants With Any Change From Baseline in Hormone Abnormalities at Years 1, 2, 3, and 4 Year 2	1.63 percentage of participants	—	1.15 percentage of participants
Percentage of Participants With Any Change From Baseline in Hormone Abnormalities at Years 1, 2, 3, and 4 Year 3	1.63 percentage of participants	2.63 percentage of participants	1.15 percentage of participants
Percentage of Participants With Any Change From Baseline in Hormone Abnormalities at Years 1, 2, 3, and 4 Year 4	0.41 percentage of participants	2.63 percentage of participants	—

SECONDARY outcome

Timeframe: Baseline, Follow-up (during 28 days after last dose of Genotropin treatment)

Population: All participants who were enrolled in the study.

Percentage of participants taking any medications other than Genotropin (concomitant medication) are reported.

Outcome measures

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=247 Participants Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=42 Participants Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=88 Participants Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Percentage of Participants With Any Concomitant Medication at Baseline and During Follow-up Baseline	83.0 percentage of participants	69.0 percentage of participants	83.0 percentage of participants
Percentage of Participants With Any Concomitant Medication at Baseline and During Follow-up During follow-up	92.3 percentage of participants	73.8 percentage of participants	88.6 percentage of participants

Adverse Events

KIMS Adult Onset Growth Hormone Deficiency (GHD)

Serious events: 57 serious events

Other events: 66 other events

Deaths: 12 deaths

Naive Adult Onset GHD

Serious events: 5 serious events

Other events: 14 other events

Deaths: 1 deaths

Childhood Onset Growth Hormone Deficiency (CO-GHD)

Serious events: 10 serious events

Other events: 15 other events

Deaths: 0 deaths

Serious adverse events

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 participants at risk Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=41 participants at risk Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 participants at risk Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pituitary tumour recurrent	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pituitary tumour benign	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Astrocytoma	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenoma benign	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine tumour	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer metastatic	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer metastatic	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Burkitt's lymphoma	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Glioblastoma	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Myocardial infarction	1.2% 3/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Cardiac failure	1.2% 3/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Atrial fibrillation	1.2% 3/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Sinus node dysfunction	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Angina pectoris	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Palpitations	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Angina unstable	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Acute myocardial infarction	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Cardiac disorders Cardiac arrest	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Pneumonia	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Influenza	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Sepsis	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Abscess	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Meningitis	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Urinary tract infection	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Periodontitis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Erysipelas	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Respiratory tract infection	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Cerebrovascular accident	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Syncope	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Headache	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Epilepsy	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Cerebrospinal fluid leakage	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Cerebral infarction	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Cerebral haemorrhage	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Carpal tunnel syndrome	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Transient ischaemic attack	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Guillain-barre syndrome	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Adrenocortical insufficiency acute	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Cortisol deficiency	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Glucocorticoid deficiency	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Hyperparat hyroidism	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Pituitary apoplexy	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Chest pain	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Adverse drug reaction	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Dysplasia	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Pyrexia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Corneal abrasion	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Medication error	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Strangulated incisional hernia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Pelvic fracture	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Head injury	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Abdominal pain	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Melaena	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Vomiting	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Abdominal pain upper	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Depression	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Abnormal behaviour	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Major depression	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Macular degeneration	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Retinal detachment	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Orthostatic hypotension	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Aortic dissection	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Congenital, familial and genetic disorders Neurofibromatosis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Ear and labyrinth disorders Vertigo	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Hepatobiliary disorders Cholecystitis	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Reproductive system and breast disorders Ovarian cyst	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Surgical and medical procedures Amputation	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.

Other adverse events

Measure	KIMS Adult Onset Growth Hormone Deficiency (GHD) n=246 participants at risk Participants were diagnosed with GHD before 2013, were previously treated with Genotropin and were followed in KIMS®. Participants continued to be diagnosed with GHD as per current medical standards, who aged greater than or equal to (\>=) 18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study. KIMS® (Pfizer international metabolic database), have data for long-term safety and treatment outcomes of adult participants treated with Genotropin in a real-world clinical setting between 1994 and 2012.	Naive Adult Onset GHD n=41 participants at risk Participants who were newly diagnosed with GHD as per current medical standards, aged \>=18 years, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.	Childhood Onset Growth Hormone Deficiency (CO-GHD) n=87 participants at risk Participants were diagnosed with CO-GHD before 2013. Participants aged \>=18 years and continued to be diagnosed with GHD as per current medical standards, received Genotropin treatment in a real world clinic setting as prescribed in clinical practice and were followed up/observed for long-term Genotropin therapy treatment outcomes in this study.
Nervous system disorders Headache	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	7.3% 3/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Dizziness	1.2% 3/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Visual field defect	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Syncope	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Sciatica	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Dementia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Hypoaesthesia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Tremor	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Somnolence	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Carotid artery stenosis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Nervous system disorders Memory impairment	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Influenza	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.3% 2/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Urinary tract infection	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Pharyngitis	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Nasopharyngitis	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Sinusitis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Gastroenteritis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Upper respiratory track infection	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Tonsillitis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Tooth infection	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Pulpitis dental	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Infections and infestations Malaria	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Back pain	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.3% 2/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Myalgia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Tendonitis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Tendon pain	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Spinal stenosis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Exostosis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Osteoporosis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Osteitis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Pain in extremity	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Dupuytren's contracture	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Bone pain	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Musculoskeletal and connective tissue disorders Muscle haemorrhage	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Fatigue	2.8% 7/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	4.9% 2/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.3% 2/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Pyrexia	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Chest pain	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
General disorders Peripheral swelling	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Prostatic specific antigen increased	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Haemoglobin decreased	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Weight increased	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Weight decreased	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Colonoscopy	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Hepatic enzyme increased	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Blood prolactin increased	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Blood testosterone increased	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Blood homocysteine increased	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Investigations Blood folate decreased	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Diarrhoea	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Abdominal pain	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Nausea	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Vomiting	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Haematemesis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Gastrointestinal disorders Abdominal pain upper	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Medication error	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Back injury	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Fall	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Radius fracture	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Fibula fracture	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Foot fracture	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Burns second degree	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Injury, poisoning and procedural complications Wound	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Hypertension	1.2% 3/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Deep vein thrombosis	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Venous thrombosis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Thrombophlebitis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Varicose vein	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Vascular disorders Aneurysm	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pituitary tumour benign	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Melanocytic naevus	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma in situ	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Depression	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	4.9% 2/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Libido decreased	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Insomnia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Acute stress disorder	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Psychiatric disorders Anxiety	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Metabolism and nutrition disorders Hyperlipidaemia	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Metabolism and nutrition disorders Diabetes mellitus	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Metabolism and nutrition disorders Dyslipidaemia	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Metabolism and nutrition disorders Vitamin D deficiency	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Adrenal insufficiency	1.2% 3/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Hyperparat hyroidism primary	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Endocrine disorders Diabetes insipidus	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Cataract	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Vitreous detachment	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Dry eye	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Diabetic retinopathy	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Visual impairment	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Eye disorders Macular oedema	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Reproductive system and breast disorders Gynaecomastia	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Reproductive system and breast disorders Dysmenorrhoea	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	2.4% 1/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Skin and subcutaneous tissue disorders Skin lesion	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Skin and subcutaneous tissue disorders Eczema	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Skin and subcutaneous tissue disorders Dry skin	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Ear and labyrinth disorders Vertigo	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Ear and labyrinth disorders Vertigo positional	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Ear and labyrinth disorders Hypoacusis	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Blood and lymphatic system disorders Anaemia	0.81% 2/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Surgical and medical procedures Knee arthroplasty	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Surgical and medical procedures Tonsillectomy	0.00% 0/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Surgical and medical procedures Gastric banding	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Pregnancy, puerperium and perinatal conditions Pregnancy	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	1.1% 1/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.
Product Issues Syringe issue	0.41% 1/246 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/41 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.	0.00% 0/87 • Baseline up to 28 days after last dose of Genotropin treatment (maximum up to 5 years) Same event may appear as an AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. Participants treated with at least 1 dose of Genotropin were evaluated for safety.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

Results disclosure agreements

• Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
• Publication restrictions are in place

Restriction type: OTHER